AACR 2020 – Biontech and Roche try to resuscitate cancer vaccines
A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history.
Neurocrine picks Takeda’s brain
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
EAN 2020 – Atara’s multiple sclerosis plan slowly takes shape
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
Macrogenics scoops its Asco bounce
A tiny glimpse at very early data has more than tripled Macrogenics’ market cap. The pressure is now on to confirm these signals.
Vir bids to enter the hepatitis B race
The first data with the RNAi project VIR-2218 mark Vir’s attempt to join a race that Arbutus appeared to crash out of last month.
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Will pending clinical readouts make it across the line?
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Roche move endorses Iteos’s Tigit widget
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
